Uranium Royalty Corp. cash flow statement UROY

In Q1 of fiscal 2027, the quarter ended Jul 31, 2026, Uranium Royalty Corp. generated $53.0 million of cash from operations.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the same quarter a year earlier.

Line
TTM
Jul 31, 2026
Q1 FY2027
Jul 31, 2026
Operating
Depreciation and amortization
—
0
Stock-based compensation
—
0
Operating cash flow
—
53
Investing
Investing cash flow
—
-266
Financing
Financing cash flow
—
40
Change in cash
Effect of exchange rate
—
-6
Net change in cash
—
-178
Ratios
Stock-based compensation to revenue
—
0.15%
Cash conversion
—
3.26x
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry
Commodity Contracts Brokers & Dealers (SIC 6221)
Listed as
UROY (Nasdaq)
Fiscal year ends
April 30
Incorporated in
DE
Headquarters
Lakewood, CO
SEC filer status
, Emerging growth company
SEC CIK
2143673

Other Commodity Contracts Brokers & Dealers companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.